Statements (46)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:medroxyprogesterone_acetate
|
| gptkbp:administrationInterval |
every 12 weeks
|
| gptkbp:alternativeTo |
contraceptive implant
combined oral contraceptives copper IUD |
| gptkbp:approvedBy |
1960s
|
| gptkbp:ATCCode |
gptkb:G03AC06
|
| gptkbp:availableOn |
many countries worldwide
|
| gptkbp:brand |
gptkb:Depo-Provera
|
| gptkbp:category |
long-acting reversible contraceptive
progestin-only contraceptive |
| gptkbp:contraindication |
known or suspected pregnancy
unexplained vaginal bleeding active thromboembolic disease |
| gptkbp:developer |
gptkb:Upjohn_Company
|
| gptkbp:duration |
about 3 months
|
| gptkbp:eliminationHalfLife |
about 50 days
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
104 mg/0.65 mL SC
150 mg/mL IM |
| gptkbp:fullName |
Depot medroxyprogesterone acetate
|
| https://www.w3.org/2000/01/rdf-schema#label |
DMPA
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
suppresses ovulation
thickens cervical mucus thins endometrial lining |
| gptkbp:metabolism |
liver
|
| gptkbp:notRecommendedFor |
adolescents for long-term use due to bone effects
women with breast cancer |
| gptkbp:pregnancyCategory |
X
|
| gptkbp:returnToFertility |
may be delayed after discontinuation
|
| gptkbp:routeOfAdministration |
intramuscular injection
subcutaneous injection |
| gptkbp:sideEffect |
headache
weight gain irregular bleeding decreased bone mineral density |
| gptkbp:storage |
room temperature
|
| gptkbp:usedFor |
contraception
|
| gptkbp:usedIn |
family planning
menstrual disorders endometriosis management |
| gptkbp:WHOModelListOfEssentialMedicines |
yes
|
| gptkbp:bfsParent |
gptkb:Depo-Provera
|
| gptkbp:bfsLayer |
7
|